関連する実験動画
Updated: Sep 9, 2025

07:42
Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
Published on: April 26, 2012
18.3K
ベンクリスティン単独投与と比較して,レボフロクサシンとビンクリスティンを投与した小児腫瘍学患者の周辺神経疾患の発生率と負担
Prerna Kumar1, Molly Meister1, Ramkumar Narendran1
1University of Illinois College of Medicine Peoria, Peoria, IL.
Journal of pediatric hematology/oncology
|August 29, 2025
まとめ
ベヴォフロクサシンとビンクリスティンを併用した小児腫瘍科の患者は,ビンクリスティンを単独で投与した患者と比較して,より多くの周辺神経疾患の症状を経験しました. これは,レボフロクサシンがこれらの脆弱な患者の神経疾患の負担を増やすことを示唆しています.
科学分野:
- 小児腫瘍学
- 薬理学について
- 神経科学
背景:
- レボフロッキサチンは,中性不全の小児腫瘍患者の感染予防のための第一線抗生物質です.
- ヴィンクリスティンは白血病と固体腫瘍に使用される重要な化学療法剤です.
- レボフロクサシンとヴィンクリスティンは両方とも,周辺神経症 (PN) と関連しています.
研究 の 目的:
- ヴィンクリスティンとレボフロクサシン (VL) で治療された小児腫瘍学患者の周辺神経症 (PN) の発生率と程度を評価する.
主な方法:
- コホート研究
- 2015年から2020年の間に治療を受けた新規診断された患者のマニュアルチャートレビュー
- ヴィンクリスティン単独 (VA) とヴィンクリスティンとレボフロクサシン (VL) を投与した患者の比較
主要な成果:
- VL群とVA群の周辺神経症の全体的な発生率は有意な差異はありません.
- VLコホートはPNの症状を有意に多く報告した.
- VLコホートは,より多くのPNカテゴリーに罹患し,追加の神経疾患の治療を必要とした.
結論:
- レボフロクサシンとビンクリスティンの併用は,小児腫瘍学患者の周辺神経病変の増加と関連しています.
- レボフロッキサチンは,ビンクリスティン誘発性神経症の症状と重症度を悪化させる.
- 両剤を投与する患者におけるPNの管理に関するさらなる調査が必要である.
関連する概念動画
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
366
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
366
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
259
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
259
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
439
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
439
Local Anesthetics: Differential Sensitivity of Nerve Fibers
929
Local anesthetics (LAs) block the sodium channels of nerve trunks, sensory nerve endings, and neuromuscular junctions. Although LAs can block all kinds of nerves, the sensitivity of nerve fibers differs according to nerve types and structures. LAs are known to block myelinated fibers faster than unmyelinated ones. Also, they block pain or sensory neurons at low concentrations without affecting the motor neurons involved in muscle contractions. This helps relieve labor pain without affecting the...
929
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
321
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
321
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K

